Baidu
map

JMCC:乳腺癌他莫昔芬耐药性可能与Snail/Slug信号有关

2014-06-26 MedSci MedSci原创

国际学术期刊Journal of Molecular Cell Biology在线发表了中国科学院上海生命科学研究院生物化学与细胞生物学研究所葛高翔研究组的最新研究成果 “Snail and Slug mediate tamoxifen resistance in breast cancer cells through activation of EGFR–ERK independen

国际学术期刊Journal of Molecular Cell Biology在线发表了中国科学院上海生命科学研究院生物化学与细胞生物学研究所葛高翔研究组的最新研究成果 “Snail and Slug mediate tamoxifen resistance in breast cancer cells through activation of EGFR–ERK independent of epithelial–mesenchymal transition”。该文揭示了乳腺癌他莫昔芬耐药性产生的分子机制。


临床上,他莫昔芬是雌激素受体阳性乳腺癌病人内分泌治疗的一线药物。他莫昔芬耐药性的产生与肿瘤的复发是临床面临的重大挑战。葛高翔研究组博士研究生姜妍、赵晓彤等的研究发现,上皮-间质转化转录因子 Snail/Slug通过上调EGFR的表达并激活其下游MAPK信号通路,诱导雌激素受体阳性乳腺癌细胞产生对他莫昔芬的耐受。这一过程不依赖 Snail/Slug引起的上皮细胞间质样转化。这一研究对阐明乳腺癌他莫昔芬耐受产生的分子机理,并鉴定他莫昔芬耐药性的特征生物标志物及治疗靶位点具 有重要意义。

该项研究工作与中国科技大学朱涛研究员合作完成,得到国家科技部(蛋白质重大研究计划)、国家自然科学基金委的经费支持。
Snail/Slug通过独立信号通路诱导乳腺癌细胞他莫昔芬耐受与上皮细胞间质样转化

原始出处:
Jiang Y, Zhao X, Xiao Q, Liu Q, Ding K, Yu F, Zhang R, Zhu T, Ge G.Snail and Slug mediate tamoxifen resistance in breast cancer cells through activation of EGFR-ERK independent of epithelial-mesenchymal transition.J Mol Cell Biol. 2014 Jun 10. pii: mju019.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=13021, encodeId=551f1302161, content=挺好的,不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97e21608061, createdName=670597691, createdTime=Tue Dec 09 09:27:00 CST 2014, time=2014-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755703, encodeId=49ae1e557038a, content=<a href='/topic/show?id=477a1031056' target=_blank style='color:#2F92EE;'>#JMCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10310, encryptionId=477a1031056, topicName=JMCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cae936999593, createdName=fyxzlh, createdTime=Sun Sep 14 08:35:00 CST 2014, time=2014-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794197, encodeId=f1d91e9419726, content=<a href='/topic/show?id=9e0a164e4e4' target=_blank style='color:#2F92EE;'>#Snail#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16474, encryptionId=9e0a164e4e4, topicName=Snail)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Jun 30 03:35:00 CST 2014, time=2014-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362704, encodeId=296c1362e04b9, content=<a href='/topic/show?id=2ebc2535658' target=_blank style='color:#2F92EE;'>#他莫昔芬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25356, encryptionId=2ebc2535658, topicName=他莫昔芬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Sat Jun 28 00:35:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
    2014-12-09 670597691

    挺好的,不错!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=13021, encodeId=551f1302161, content=挺好的,不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97e21608061, createdName=670597691, createdTime=Tue Dec 09 09:27:00 CST 2014, time=2014-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755703, encodeId=49ae1e557038a, content=<a href='/topic/show?id=477a1031056' target=_blank style='color:#2F92EE;'>#JMCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10310, encryptionId=477a1031056, topicName=JMCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cae936999593, createdName=fyxzlh, createdTime=Sun Sep 14 08:35:00 CST 2014, time=2014-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794197, encodeId=f1d91e9419726, content=<a href='/topic/show?id=9e0a164e4e4' target=_blank style='color:#2F92EE;'>#Snail#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16474, encryptionId=9e0a164e4e4, topicName=Snail)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Jun 30 03:35:00 CST 2014, time=2014-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362704, encodeId=296c1362e04b9, content=<a href='/topic/show?id=2ebc2535658' target=_blank style='color:#2F92EE;'>#他莫昔芬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25356, encryptionId=2ebc2535658, topicName=他莫昔芬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Sat Jun 28 00:35:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
    2014-09-14 fyxzlh
  3. [GetPortalCommentsPageByObjectIdResponse(id=13021, encodeId=551f1302161, content=挺好的,不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97e21608061, createdName=670597691, createdTime=Tue Dec 09 09:27:00 CST 2014, time=2014-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755703, encodeId=49ae1e557038a, content=<a href='/topic/show?id=477a1031056' target=_blank style='color:#2F92EE;'>#JMCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10310, encryptionId=477a1031056, topicName=JMCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cae936999593, createdName=fyxzlh, createdTime=Sun Sep 14 08:35:00 CST 2014, time=2014-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794197, encodeId=f1d91e9419726, content=<a href='/topic/show?id=9e0a164e4e4' target=_blank style='color:#2F92EE;'>#Snail#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16474, encryptionId=9e0a164e4e4, topicName=Snail)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Jun 30 03:35:00 CST 2014, time=2014-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362704, encodeId=296c1362e04b9, content=<a href='/topic/show?id=2ebc2535658' target=_blank style='color:#2F92EE;'>#他莫昔芬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25356, encryptionId=2ebc2535658, topicName=他莫昔芬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Sat Jun 28 00:35:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
    2014-06-30 lilianxiang
  4. [GetPortalCommentsPageByObjectIdResponse(id=13021, encodeId=551f1302161, content=挺好的,不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97e21608061, createdName=670597691, createdTime=Tue Dec 09 09:27:00 CST 2014, time=2014-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755703, encodeId=49ae1e557038a, content=<a href='/topic/show?id=477a1031056' target=_blank style='color:#2F92EE;'>#JMCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10310, encryptionId=477a1031056, topicName=JMCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cae936999593, createdName=fyxzlh, createdTime=Sun Sep 14 08:35:00 CST 2014, time=2014-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794197, encodeId=f1d91e9419726, content=<a href='/topic/show?id=9e0a164e4e4' target=_blank style='color:#2F92EE;'>#Snail#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16474, encryptionId=9e0a164e4e4, topicName=Snail)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Jun 30 03:35:00 CST 2014, time=2014-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362704, encodeId=296c1362e04b9, content=<a href='/topic/show?id=2ebc2535658' target=_blank style='color:#2F92EE;'>#他莫昔芬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25356, encryptionId=2ebc2535658, topicName=他莫昔芬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Sat Jun 28 00:35:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]

相关资讯

ASCO 2014:曲妥珠单抗是HER2阳性早期乳腺癌辅助治疗的标准(ALTTO研究)

中国医学科学院肿瘤医院 徐兵河 江苏省肿瘤医院 冯继峰 人表皮生长因子受体2(HER2)阳性乳腺癌的双靶向治疗是近年来的研究热点,从早期乳腺癌的新辅助治疗到晚期乳腺癌的姑息治疗,再到本届ASCO年会公布的ALTTO研究都关注这样的学术热点。在美国中部时间6月1日下午举行的全体大会报告(Plenary Session)专场中,ALTTO研究作为探讨曲妥珠单抗与拉帕替尼双靶向辅助治疗HER2阳性

ASCO 2014:gBRCA突变和家族史是三阴性乳腺癌pCR高的预测因素

卡铂在gBRCA基因突变的三阴性乳腺癌">乳腺癌患者中作用突出 题目:使用含卡铂类抗癌药物新辅助化疗,对种系BRCA(gBRCA)突变和三阴性乳腺癌(TNBC)患者病理完全缓解率(pCR)的影响:来自GeparSixto的结果Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant

Cancer:乳腺癌前期HER2诊断存在4%假阴性检测误差

Dartmouth-Hitchcock Medical Center的科研人员通过对530名患有乳腺癌的患者样本进行重新检测,发现其中有22个样本的癌症分型是错误的。原来诊断方法包括免疫组化和FISH技术。该结果于本月13日发表在了《癌症》杂志上。552例患者被诊断为HER2阴性乳腺癌,发现22例(4%)实际上为HER2阳性(95%CI:2.5%-5.7%)。这22例患者,与正确诊断的患者相比,

BMJ:少吃红肉或有助预防乳腺癌

一项新研究发现,常年食用过多红肉和加工肉制品可能增加患乳腺癌的风险。但专家也指出,若要确定吃红肉与患乳腺癌风险之间是否存在必然联系,还需更多研究加以证实。【原文下载】 新一期《英国医学杂志》(BMJ)刊登美国哈佛大学等机构研究人员的报告说,他们对约8.9万名24岁至43岁的女性进行了超过20年的跟踪研究,调查了她们日常饮食习惯和健康记录,并参考年龄、体重、吸烟习惯和乳腺癌家族病史等因素。

PLoS Med:多痣女孩儿可能会增加乳腺癌发病风险

近日刊登在PLOS Medicine上的两篇研究报告指出,女性痣数量(皮肤色素痣)可能与乳腺癌发病风险相关。 但是该研究没有得出确切结论证明女性皮肤色素痣数量增多会增加乳腺癌发病风险,而实际上研究人员仅仅解释了两者之间可能存在的激素及基因关联。 其中一篇研究的主要作者,隶属于国家健康与医学研究院的Kvaskoff表示,“这不会成为女性新的困扰,我认为多痣与乳腺癌并没有直接的因果关系。” 研究

Oncotarget:CXCR4在乳腺癌和正常细胞中起着不同的作用

在制定有效的癌症疗法中的一个关键步骤是确定正常,健康细胞和癌细胞之间的差异,这些差异可以被利用来特异性杀伤肿瘤细胞。曼彻斯特科学家一项新的研究第一次对比了一种特定的蛋白质CXCR4在正常和癌变乳腺干细胞中的影响,了解CXCR4对上述细胞的差异性意味着它可以被利用来开发乳腺癌更有针对性的治疗。CXCR4已经在23个不同类型的癌症中被发现,并已与癌症预后较差相关。现在,研究人员研究CXCR4在正常乳腺

Baidu
map
Baidu
map
Baidu
map